Ketolides: A New Class of Antibacterial Agents for Treatment of Community-Acquired Respiratory Tract Infections in a Primary Care Setting

Clark, Jeffrey Paul; Langston, Edward
September 2003
Mayo Clinic Proceedings;Sep2003, Vol. 78 Issue 9, p1113
Academic Journal
Examines the use of telithromycin ketolide antibacterial agent to treat community-acquired respiratory tract infections. Drug activity against respiratory pathogens; Drug effectiveness and safety; Drug tolerance; Drug interaction potential.


Related Articles

  • Gemifloxacin: A broad-spectrum oral quinolone for treatment of respiratory and urinary tract infections. Lomaestro, Ben M. // Formulary;Dec2000, Vol. 35 Issue 12, p961 

    Examines the pharmacokinetic and pharmacodynamic characteristics of gemifloxacin, a potent fluoroquinolone, against several pathogens. Use of gemifloxacin in the treatment of respiratory and urinary tract infections; Drug interactions; Adverse effect profile.

  • Telithromycin: A Viewpoint by S. Ragnar Norrby. Norrby, S.R. // Drugs;Apr2001, Vol. 61 Issue 6, p830 

    Comments on the use of telithromycin as an antibiotic against pneumococci. Diseases which can be treated by telithromycin; Effectivity of telithromycin in the oral treatment of respiratory tract infections.

  • Responsible Prescribing for Upper Respiratory Tract Infections. Turnidge, J. // Drugs;Nov2001, Vol. 61 Issue 14, p2065 

    Upper respiratory tract infections (URTIs) are responsible for a large amount of community antibacterial use worldwide. Recent systematic reviews have demonstrated that most URTIs resolve naturally, even when bacteria are the cause. The high consumer expectation for antibacterials in URTIs...

  • A Critical Review of the Fluoroquinolones: Focus on Respiratory Infections. Zhanel, G.G.; Ennis, K.; Vercaigne, L.; Walkty, A.; Gin, A.S.; Embil, J.; Smith, H.; Hoban, D.J. // Drugs;2002, Vol. 62 Issue 1, p13 

    The new fluoroquinolones (clinafloxacin, gatifloxacin, gemifloxacin, grepafloxacin, levofloxacin, moxifloxacin, sitafloxacin, sparfloxacin and trovafloxacin) offer excellent activity against Gram-negative bacilli and improved Gram-positive activity (e.g. against Streptococcus pneumoniae and...

  • Fluoroquinolone-Associated Tendinopathy: A Critical Review of the Literature. Khaliq, Yasmin; Zhanel, George G. // Clinical Infectious Diseases;6/1/2003, Vol. 36 Issue 11, p1404 

    With the expanded use of fluoroquinolones for the treatment of community-acquired respiratory infections and reports of tendon injury linked to the use of these agents, we reviewed the literature to investigate the frequency and strength of this association. Ninety-eight case reports were...

  • The treatment of acute bacterial sinusitis: No change is good medicine. Le Saux, Nicole // CMAJ: Canadian Medical Association Journal;3/25/2008, Vol. 178 Issue 7, p865 

    The article focuses on treating acute bacterial sinusitis. According to the author, there are clinical trials which show that majority of patients with acute bacterial sinusitis have a 50 to 70 percent chance of recovery without antibiotic therapy. The article also provides information on...

  • Clinical Perspectives on New Antimicrobials: Focus on Fluoroquinolones. Talan, David A. // Clinical Infectious Diseases;3/15/2001 Supplement 1, Vol. 32, pS64 

    Respiratory tract infections are the most common infectious presentation in the community and hospital settings and are a major cause of morbidity and mortality worldwide. Recently, newer fluoroquinolones have been recommended for the treatment of these infections. Among them, moxifloxacin shows...

  • New fluoroquinolone has dual activity against resistant bugs. LoBuono, Charlotte // Drug Topics;5/5/2003, Vol. 147 Issue 9, p16 

    Reports on the U.S. Food and Drug Administration's approval of gemifloxacin for the treatment of acute exacerbations of chronic bronchitis. Fourth-generation fluoroquinolone with dual activity against bacteria to treat community-acquired respiratory infections; Inhibition of DNA synthesis...

  • Antibiotic Use Declines Overall, While Use of Broad-Spectrum Increases.  // Clinical Oncology Alert;Oct2009 Supplement, p1 

    The article reports on a decline in antibiotics use for the treatment of acute respiratory tract infections (ARTI) based on data obtained between 1995 and 2006. Antibiotics trends were examined using a national database for ARTI. It showed that children below the age of 5 were less likely to be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics